{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:13:43Z","timestamp":1784121223235,"version":"3.55.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The association between human leukocyte antigen (HLA) variants and allopurinol-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) was evaluated through a pooled analysis of published studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A comprehensive search was performed in multiple databases, including PubMed, MEDLINE, ISI Web of Knowledge, EMBASE, Cochrane Register of Controlled Trials, and Science Direct. Studies investigating the association between HLA alleles with allopurinol-induced SJS or TEN were retrieved, and the data were independently extracted. The overall odds ratios (ORs) with corresponding 95% confidence intervals were calculated to determine the association between the presence of HLA variant in at least one allele and allopurinol-induced SJS or TEN. To test the robustness of the meta-analysis results, a sensitivity analysis was performed by removing each study one at a time and calculating the pooled ORs of the remaining studies. The fixed-effects and random-effects models were used to pool the collected data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 4 studies with 81 allopurinol-induced SJS or TEN cases and matched controls (allopurinol-tolerant patients) or population controls (general population) were identified. SJS and TEN were found to be significantly associated with HLA-A*33:03 and HLA-C*03:02 alleles in both groups of studies with matched controls and population controls. All of the pooled ORs were not significantly affected by the remaining studies and different modeling methods, indicating robust results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A strong association was found between HLA-A*33:03 and HLA-C*03:02 alleles and allopurinol-induced SJS or TEN, especially in an Asian population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2146\/ajhp160243","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T10:45:15Z","timestamp":1493030715000},"page":"e183-e192","source":"Crossref","is-referenced-by-count":13,"title":["Association of human leukocyte antigen variants and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis"],"prefix":"10.1093","volume":"74","author":[{"given":"Xingang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Sen","family":"Sun","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Western New England University, Springfield, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2020071622284950500_b1-074e183","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2020071622284950500_b2-074e183","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"2020071622284950500_b3-074e183","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"2020071622284950500_b4-074e183","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1515\/cclm-2014-0251","article-title":"Detection of HLA-B*58:01 with TaqMan assay and its association with allopurinol-induced sCADR","volume":"53","author":"Zhang","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2020071622284950500_b5-074e183","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1468-3083.2011.04313.x","article-title":"Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department\u2013Cagliari University (Italy)","volume":"26","author":"Atzori","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020071622284950500_b6-074e183","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"2020071622284950500_b7-074e183","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2020071622284950500_b8-074e183","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"2020071622284950500_b9-074e183","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020071622284950500_b10-074e183","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"2020071622284950500_b11-074e183","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"2020071622284950500_b12-074e183","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"2020071622284950500_b13-074e183","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1744-313X.2011.01011.x","article-title":"A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"38","author":"Cristallo","year":"2011","journal-title":"Int J Immunogenet"},{"key":"2020071622284950500_b14-074e183","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/tpj.2011.41","article-title":"A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"13","author":"Tohkin","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"2020071622284950500_b15-074e183","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","article-title":"Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01","volume":"192","author":"Yun","year":"2014","journal-title":"J Immunol"},{"key":"2020071622284950500_b16-074e183","first-page":"107","article-title":"HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson syndrome\/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies","volume":"65","author":"Li","year":"2015","journal-title":"Drug Res"},{"key":"2020071622284950500_b17-074e183","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","article-title":"The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations","volume":"156","author":"Shiohara","year":"2007","journal-title":"Br J Dermatol"},{"key":"2020071622284950500_b18-074e183","unstructured":"Wells\n              G\n            \n            \n              Shea\n              B\n            \n            \n              O\u2019Connell\n              D\n            \n          . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [EB\/OL]. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (accessed 2017 Jan 29)."},{"key":"2020071622284950500_b19-074e183","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/gepi.20048","article-title":"Heterogeneity testing in meta-analysis of genome searches","volume":"28","author":"Zintzaras","year":"2005","journal-title":"Genet Epidemiol"},{"key":"2020071622284950500_b20-074e183","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","article-title":"Quantitative synthesis in systematic reviews","volume":"127","author":"Lau","year":"1997","journal-title":"Ann Intern Med"},{"key":"2020071622284950500_b21-074e183","first-page":"17789","article-title":"Correlation of lymphovascular invasion with clinicopathological factors in invasive breast cancer: a meta-analysis","volume":"8","author":"Shen","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"2020071622284950500_b22-074e183","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2020071622284950500_b23-074e183","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000102045","article-title":"Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?","volume":"215","author":"Dainichi","year":"2007","journal-title":"Dermatology"},{"key":"2020071622284950500_b24-074e183","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdermsci.2013.04.013","article-title":"HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population","volume":"71","author":"Niihara","year":"2013","journal-title":"J Dermatol Sci"},{"key":"2020071622284950500_b25-074e183","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1620\/tjem.233.95","article-title":"HLA-DR9 and DR14 are associated with the allopurinol-induced hypersensitivity in hematologic malignancy","volume":"233","author":"Jung","year":"2014","journal-title":"Tohoku J Exp Med"},{"key":"2020071622284950500_b26-074e183","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-010611-134701","article-title":"Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex","volume":"52","author":"Bharadwaj","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2020071622284950500_b27-074e183","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","article-title":"Human leukocyte antigens and drug hypersensitivity","volume":"7","author":"Chung","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2020071622284950500_b28-074e183","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"2020071622284950500_b29-074e183","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/all.12008","article-title":"Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA","volume":"67","author":"Yun","year":"2012","journal-title":"Allergy"},{"key":"2020071622284950500_b30-074e183","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.pa.28.040188.002055","article-title":"The immunologic and metabolic basis of drug hypersensitivities","volume":"28","author":"Pohl","year":"1988","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2020071622284950500_b31-074e183","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1034\/j.1398-9995.2002.02161.x","article-title":"Pathogenesis of drug-induced exanthems","volume":"57","author":"Pichler","year":"2002","journal-title":"Allergy"},{"key":"2020071622284950500_b32-074e183","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrg2361","article-title":"Linkage disequilibrium\u2014understanding the evolutionary past and mapping the medical future","volume":"9","author":"Slatkin","year":"2008","journal-title":"Nat Rev Genet"},{"key":"2020071622284950500_b33-074e183","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1750-1172-6-52","article-title":"Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe","volume":"6","author":"Genin","year":"2011","journal-title":"Orphanet J Rare Dis"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/9\/e183\/28450612\/ajhpe183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/9\/e183\/28450612\/ajhpe183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T10:50:47Z","timestamp":1594983047000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/9\/e183\/5102773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,1]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160243","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,1]]},"published":{"date-parts":[[2017,5,1]]}}}